CELL INTELLIGENCE · 肿瘤细胞治疗研究

对的钥匙，错的锁：TIGIT 检查点阻断与精准免疫治疗之路

The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.

靶向 NY-ESO-1 的保守高亲和力 TCR 工程化 CD4 TCR T 细胞用于癌症晚期细胞治疗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

新辅助化疗期间的预康复可增强食管腺癌肿瘤的免疫反应：一项随机对照试验

Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: A randomized controlled tr

我们表明，在 NAC 期间进行运动训练，相比不运动能促进更高水平的心肺适能，与 TIL 频率增加和 TLS 成熟度提高相关。这些数据提示，NAC 期间运动可增强免疫系统。未来有必要开展研究以了解其临床意义。

晚期胃食管癌的 CAR-T 细胞治疗

CAR T-cell therapy in advanced gastro-oesophageal cancer.

探讨 NY-ESO-1 表达和 HLA 亚型在转移性滑膜肉瘤中的预后影响

Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma.

原发肿瘤队列在调整重要预后因素后，未显示 NY-ESO-1 表达与 OS 之间存在关联（包括按 HLA-A∗02 亚型和治疗线数进行分层），这可能是由于样本量较小所致。

免疫球蛋白超家族配体 B7H6 使 T 细胞反应受 NK 细胞监视

The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.

TIL（肿瘤浸润淋巴细胞）介导 NY-ESO-1 表达前列腺癌患者的完全且持久缓解

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.

评估 pegenzileukin（SAR444245/THOR-707）联合 pembrolizumab 或 cetuximab 治疗晚期转移性胃肠道癌：PEGATHOR 2 期研究

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGAT

CD4+、CD8+和 FOXP3+TIL（肿瘤浸润淋巴细胞）及其比值与食管鳞状细胞癌临床病理参数及肿瘤出芽的关系

The Relationship of CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes and Their Ratios With Clinicopathological Parameters and Tumor Budding in Es

紧密连接蛋白 claudin 6 是食管和胃腺癌患者个体化治疗的潜在靶点且与不良预后相关

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associ

CLDN6 mRNA 高表达与调控细胞生长、增殖和细胞-基质相互作用的多种不同生物学通路失调相关。